Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.
Day 1

SIGNIFY: Ivabradine does not reduce events in patients with stable coronary disease

solaci
solaci
461
0

The increase in heart rate in the setting of chronic coronary artery disease is associated with poor prognosis, especially increased risk of acute myocardial infarction. Reducing heart rate with ibravadina inhibitor may confer symptomatic benefit of angina and reduce coronary events in patients with chronic coronary disease and a resting heart rate ≥ 70 bpm. After a mean follow up of 27.8 months, no significant difference was observed for the occurrence of events between ibravadina group and the placebo group. 

9_kim_fox
Kim Fox
2014-08-31

Original title: Ivabradine in patients with stable coronary artery disease without clinical heart failure: The results of SIGNIFY.

Previous article
ODYSSEYCOMBO II: Alirocumab more effective than ezetimibe when statins are insufficient
Next article
ODYSSEY FH I and FH II: Alirocumab in patients with heterozygous familial hypercholesterolemia
solaci
solaci

More articles by this author

ODYSSEY LONG TERM: Safety and efficacy of long-term alirocumab

solaci - 0
This was a prospective, randomized, controlled study comparing monoclonal antibody alirocumab with placebo in patients with hypercholesterolemia and high cardiovascular risk. At 24 weeks...

LISTEN: Rosuvastatin versus atorvastatin in Japanese diabetic patients

solaci - 0
The treatment of hyperlipidemia is useful in primary and secondary prevention of chronic heart disease and stroke, particularly in diabetic patients. Many statins may...

COPPS-2: Colchicine for prevention of post-pericardiotomy syndrome and postoperative atrial fibrillation

solaci - 0
180 patients with colchicine 0.5 mg twice daily from 48-72 hs. before surgery versus 180 patients to placebo were randomized. The medication was continued...

ODYSSEY FH I and FH II: Alirocumab in patients with heterozygous familial hypercholesterolemia

solaci - 0
The study included patients with a diagnosis of heterozygous familial hypercholesterolemia who were receiving the maximum tolerated dose of randomized statin alirocumab 75 mg...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 1

ODYSSEY LONG TERM: Safety and efficacy of long-term alirocumab

This was a prospective, randomized, controlled study comparing monoclonal antibody alirocumab with placebo in patients with hypercholesterolemia and high cardiovascular...
solaci -
SOLACI Sessionsspot_img

Recent Articles

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Dr. Juan Manuel Pérez - 0
Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

Left Atrial Appendage Closure: Implantation Depth Could Determine Thrombosis Risk

Dr. Andrés Rodríguez - 0
Left atrial appendage closure (LAAC) has undergone significant advances over the past two decades. This progress has been driven by the development of new...

Influence of cusp-overlap and three-cusp coplanar techniques on new-onset conduction disturbances after TAVI

Dr. Juan Manuel Pérez - 0
New-onset conduction disturbances remain one of the most frequent complications after transcatheter aortic valve implantation (TAVI), being associated with worse long-term clinical outcomes. Among...